Biogen Reports Record Revenues for Both the Full Year and Fourth Quarter of 2017, $12.3 Billion and $3.3 Billion, Respectively

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 6/23/2026

1. SPCX
2. META
3. ABBV
4. SPY
5. FDX
6. IBM
7. MU
8. PFE
9. AWK
10. ACN

Go back to Biogen Reports Record Revenues for Both the Full Year and Fourth Quarter of 2017, $12.3 Billion and $3.3 Billion, Respectively

Forward Pharma (FWP) Halted LUDP; Shares Down 19%

January 29, 2018 11:20 AM EST

Forward Pharma (NASDAQ: FWP) halted LUDP; Shares down 19% as trading resumes

... More

Biogen (BIIB) PT Raised to $400 at Oppenheimer

January 26, 2018 6:46 AM EST

Oppenheimer raised its price target on Biogen (NASDAQ: BIIB) to $400.00 (from $380.00) while maintaining a Outperform rating.

Analyst Jay Olson commented, "BIIB shares outperformed yesterday (+2.1% vs. NBI +0.7% and S&P 500 +0.1%) on strong 4Q17 financial results and confidence expressed by management regarding execution on key... More

Biogen (BIIB) PT Raised to $408 at Cowen

January 25, 2018 1:12 PM EST

Cowen raised its price target on Biogen (NASDAQ: BIIB) to $408.00 (from $338.00) while maintaining an Outperform rating.

Analyst Eric Schmidt highlighted that the MS franchise is steady while Spinraza sales were strong as the drug's ex-U.S. launch has accelerated.

... More

Biogen (BIIB) Misses Q4 EPS by 19c, Revenue Beats; Offers Outlook

January 25, 2018 6:31 AM EST

(Updated - January 25, 2018 6:33 AM EST)

Biogen (NASDAQ: BIIB) reported Q4 EPS of $5.26, $0.19 worse than the analyst estimate of $5.45. Revenue for the quarter came in at $3.31 billion versus the consensus estimate of $3.08 billion.

GUIDANCE:

Biogen sees FY2018 EPS of $24.20-$25.20... More